SARS-CoV-2 Spike Protein Induces Hemagglutination: Implications for COVID-19 Morbidities and Therapeutics and for Vaccine Adverse Effects
et al., bioRxiv, doi:10.1101/2022.11.24.517882, Nov 2022
Ivermectin for COVID-19
4th treatment shown to reduce risk in
August 2020, now with p < 0.00000000001 from 106 studies, recognized in 24 countries.
No treatment is 100% effective. Protocols
combine treatments.
6,300+ studies for
210+ treatments. c19early.org
|
In vitro study showing that ivermectin blocked hemagglutination (clumping of red blood cells) when added to red blood cells prior to SARS-CoV-2 spike protein, and reversed hemagglutination when added afterwards.
Spike protein from four lineages of SARS-CoV-2 induced hemagglutination in human red blood cells, with omicron inducing hemagglutination at a significantly lower concentration. Authors note that the results supports other indications that spike protein-induced red blood cell clumping, as well as viral attachments to other blood cells and endothelial cells, may be a significant factor in COVID-19 morbidities.
74 preclinical studies support the efficacy of ivermectin for COVID-19:
Ivermectin, better known for antiparasitic activity, is a broad spectrum antiviral with activity against many viruses including H7N771, Dengue37,72,73 , HIV-173, Simian virus 4074, Zika37,75,76 , West Nile76, Yellow Fever77,78, Japanese encephalitis77, Chikungunya78, Semliki Forest virus78, Human papillomavirus57, Epstein-Barr57, BK Polyomavirus79, and Sindbis virus78.
Ivermectin inhibits importin-α/β-dependent nuclear import of viral proteins71,73,74,80 , shows spike-ACE2 disruption at 1nM with microfluidic diffusional sizing38, binds to glycan sites on the SARS-CoV-2 spike protein preventing interaction with blood and epithelial cells and inhibiting hemagglutination41,81, shows dose-dependent inhibition of wildtype and omicron variants36, exhibits dose-dependent inhibition of lung injury61,66, may inhibit SARS-CoV-2 via IMPase inhibition37, may inhibit SARS-CoV-2 induced formation of fibrin clots resistant to degradation9, inhibits SARS-CoV-2 3CLpro54, may inhibit SARS-CoV-2 RdRp activity28, may minimize viral myocarditis by inhibiting NF-κB/p65-mediated inflammation in macrophages60, may be beneficial for COVID-19 ARDS by blocking GSDMD and NET formation82, may interfere with SARS-CoV-2's immune evasion via ORF8 binding4, may inhibit SARS-CoV-2 by disrupting CD147 interaction83-86, shows protection against inflammation, cytokine storm, and mortality in an LPS mouse model sharing key pathological features of severe COVID-1959,87, may be beneficial in severe COVID-19 by binding IGF1 to inhibit the promotion of inflammation, fibrosis, and cell proliferation that leads to lung damage8, may minimize SARS-CoV-2 induced cardiac damage40,48, may counter immune evasion by inhibiting NSP15-TBK1/KPNA1 interaction and restoring IRF3 activation88, may disrupt SARS-CoV-2 N and ORF6 protein nuclear transport and their suppression of host interferon responses1, reduces TAZ/YAP nuclear import, relieving SARS-CoV-2-driven suppression of IRF3 and NF-κB antiviral pathways35, increases Bifidobacteria which play a key role in the immune system89, has immunomodulatory51 and anti-inflammatory70,90 properties, and has an extensive and very positive safety profile91.
1.
Gayozo et al., Binding affinities analysis of ivermectin, nucleocapsid and ORF6 proteins of SARS-CoV-2 to human importins α isoforms: A computational approach, Biotecnia, doi:10.18633/biotecnia.v27.2485.
2.
Lefebvre et al., Characterization and Fluctuations of an Ivermectin Binding Site at the Lipid Raft Interface of the N-Terminal Domain (NTD) of the Spike Protein of SARS-CoV-2 Variants, Viruses, doi:10.3390/v16121836.
3.
Haque et al., Exploring potential therapeutic candidates against COVID-19: a molecular docking study, Discover Molecules, doi:10.1007/s44345-024-00005-5.
4.
Bagheri-Far et al., Non-spike protein inhibition of SARS-CoV-2 by natural products through the key mediator protein ORF8, Molecular Biology Research Communications, doi:10.22099/mbrc.2024.50245.2001.
5.
de Oliveira Só et al., In Silico Comparative Analysis of Ivermectin and Nirmatrelvir Inhibitors Interacting with the SARS-CoV-2 Main Protease, Preprints, doi:10.20944/preprints202404.1825.v1.
6.
Agamah et al., Network-based multi-omics-disease-drug associations reveal drug repurposing candidates for COVID-19 disease phases, ScienceOpen, doi:10.58647/DRUGARXIV.PR000010.v1.
7.
Oranu et al., Validation of the binding affinities and stabilities of ivermectin and moxidectin against SARS-CoV-2 receptors using molecular docking and molecular dynamics simulation, GSC Biological and Pharmaceutical Sciences, doi:10.30574/gscbps.2024.26.1.0030.
8.
Zhao et al., Identification of the shared gene signatures between pulmonary fibrosis and pulmonary hypertension using bioinformatics analysis, Frontiers in Immunology, doi:10.3389/fimmu.2023.1197752.
9.
Vottero et al., Computational Prediction of the Interaction of Ivermectin with Fibrinogen, Molecular Sciences, doi:10.3390/ijms241411449.
10.
Chellasamy et al., Docking and molecular dynamics studies of human ezrin protein with a modelled SARS-CoV-2 endodomain and their interaction with potential invasion inhibitors, Journal of King Saud University - Science, doi:10.1016/j.jksus.2022.102277.
11.
Umar et al., Inhibitory potentials of ivermectin, nafamostat, and camostat on spike protein and some nonstructural proteins of SARS-CoV-2: Virtual screening approach, Jurnal Teknologi Laboratorium, doi:10.29238/teknolabjournal.v11i1.344.
12.
Alvarado et al., Interaction of the New Inhibitor Paxlovid (PF-07321332) and Ivermectin With the Monomer of the Main Protease SARS-CoV-2: A Volumetric Study Based on Molecular Dynamics, Elastic Networks, Classical Thermodynamics and SPT, Computational Biology and Chemistry, doi:10.1016/j.compbiolchem.2022.107692.
13.
Aminpour et al., In Silico Analysis of the Multi-Targeted Mode of Action of Ivermectin and Related Compounds, Computation, doi:10.3390/computation10040051.
14.
Parvez et al., Insights from a computational analysis of the SARS-CoV-2 Omicron variant: Host–pathogen interaction, pathogenicity, and possible drug therapeutics, Immunity, Inflammation and Disease, doi:10.1002/iid3.639.
15.
Francés-Monerris et al., Microscopic interactions between ivermectin and key human and viral proteins involved in SARS-CoV-2 infection, Physical Chemistry Chemical Physics, doi:10.1039/D1CP02967C.
16.
González-Paz et al., Comparative study of the interaction of ivermectin with proteins of interest associated with SARS-CoV-2: A computational and biophysical approach, Biophysical Chemistry, doi:10.1016/j.bpc.2021.106677.
17.
González-Paz (B) et al., Structural Deformability Induced in Proteins of Potential Interest Associated with COVID-19 by binding of Homologues present in Ivermectin: Comparative Study Based in Elastic Networks Models, Journal of Molecular Liquids, doi:10.1016/j.molliq.2021.117284.
18.
Rana et al., A Computational Study of Ivermectin and Doxycycline Combination Drug Against SARS-CoV-2 Infection, Research Square, doi:10.21203/rs.3.rs-755838/v1.
19.
Muthusamy et al., Virtual Screening Reveals Potential Anti-Parasitic Drugs Inhibiting the Receptor Binding Domain of SARS-CoV-2 Spike protein, Journal of Virology & Antiviral Research, www.scitechnol.com/abstract/virtual-screening-reveals-potential-antiparasitic-drugs-inhibiting-the-receptor-binding-domain-of-sarscov2-spike-protein-16398.html.
20.
Qureshi et al., Mechanistic insights into the inhibitory activity of FDA approved ivermectin against SARS-CoV-2: old drug with new implications, Journal of Biomolecular Structure and Dynamics, doi:10.1080/07391102.2021.1906750.
21.
Schöning et al., Highly-transmissible Variants of SARS-CoV-2 May Be More Susceptible to Drug Therapy Than Wild Type Strains, Research Square, doi:10.21203/rs.3.rs-379291/v1.
22.
Bello et al., Elucidation of the inhibitory activity of ivermectin with host nuclear importin α and several SARS-CoV-2 targets, Journal of Biomolecular Structure and Dynamics, doi:10.1080/07391102.2021.1911857.
23.
Udofia et al., In silico studies of selected multi-drug targeting against 3CLpro and nsp12 RNA-dependent RNA-polymerase proteins of SARS-CoV-2 and SARS-CoV, Network Modeling Analysis in Health Informatics and Bioinformatics, doi:10.1007/s13721-021-00299-2.
24.
Choudhury et al., Exploring the binding efficacy of ivermectin against the key proteins of SARS-CoV-2 pathogenesis: an in silico approach, Future Medicine, doi:10.2217/fvl-2020-0342.
25.
Kern et al., Modeling of SARS-CoV-2 Treatment Effects for Informed Drug Repurposing, Frontiers in Pharmacology, doi:10.3389/fphar.2021.625678.
26.
Saha et al., The Binding mechanism of ivermectin and levosalbutamol with spike protein of SARS-CoV-2, Structural Chemistry, doi:10.1007/s11224-021-01776-0.
27.
Eweas et al., Molecular Docking Reveals Ivermectin and Remdesivir as Potential Repurposed Drugs Against SARS-CoV-2, Frontiers in Microbiology, doi:10.3389/fmicb.2020.592908.
28.
Parvez (B) et al., Prediction of potential inhibitors for RNA-dependent RNA polymerase of SARS-CoV-2 using comprehensive drug repurposing and molecular docking approach, International Journal of Biological Macromolecules, doi:10.1016/j.ijbiomac.2020.09.098.
29.
Francés-Monerris (B) et al., Has Ivermectin Virus-Directed Effects against SARS-CoV-2? Rationalizing the Action of a Potential Multitarget Antiviral Agent, ChemRxiv, doi:10.26434/chemrxiv.12782258.v1.
30.
Kalhor et al., Repurposing of the approved small molecule drugs in order to inhibit SARS-CoV-2 S protein and human ACE2 interaction through virtual screening approaches, Journal of Biomolecular Structure and Dynamics, doi:10.1080/07391102.2020.1824816.
31.
Swargiary, A., Ivermectin as a promising RNA-dependent RNA polymerase inhibitor and a therapeutic drug against SARS-CoV2: Evidence from in silico studies, Research Square, doi:10.21203/rs.3.rs-73308/v1.
32.
Maurya, D., A Combination of Ivermectin and Doxycycline Possibly Blocks the Viral Entry and Modulate the Innate Immune Response in COVID-19 Patients, American Chemical Society (ACS), doi:10.26434/chemrxiv.12630539.v1.
33.
Lehrer et al., Ivermectin Docks to the SARS-CoV-2 Spike Receptor-binding Domain Attached to ACE2, In Vivo, 34:5, 3023-3026, doi:10.21873/invivo.12134.
34.
Suravajhala et al., Comparative Docking Studies on Curcumin with COVID-19 Proteins, Preprints, doi:10.20944/preprints202005.0439.v3.
35.
Kofler et al., M-Motif, a potential non-conventional NLS in YAP/TAZ and other cellular and viral proteins that inhibits classic protein import, iScience, doi:10.1016/j.isci.2025.112105.
36.
Shahin et al., The selective effect of Ivermectin on different human coronaviruses; in-vitro study, Research Square, doi:10.21203/rs.3.rs-4180797/v1.
37.
Jitobaom et al., Identification of inositol monophosphatase as a broad‐spectrum antiviral target of ivermectin, Journal of Medical Virology, doi:10.1002/jmv.29552.
38.
Fauquet et al., Microfluidic Diffusion Sizing Applied to the Study of Natural Products and Extracts That Modulate the SARS-CoV-2 Spike RBD/ACE2 Interaction, Molecules, doi:10.3390/molecules28248072.
39.
García-Aguilar et al., In Vitro Analysis of SARS-CoV-2 Spike Protein and Ivermectin Interaction, International Journal of Molecular Sciences, doi:10.3390/ijms242216392.
40.
Liu et al., SARS-CoV-2 viral genes Nsp6, Nsp8, and M compromise cellular ATP levels to impair survival and function of human pluripotent stem cell-derived cardiomyocytes, Stem Cell Research & Therapy, doi:10.1186/s13287-023-03485-3.
41.
Boschi et al., SARS-CoV-2 Spike Protein Induces Hemagglutination: Implications for COVID-19 Morbidities and Therapeutics and for Vaccine Adverse Effects, bioRxiv, doi:10.1101/2022.11.24.517882.
42.
De Forni et al., Synergistic drug combinations designed to fully suppress SARS-CoV-2 in the lung of COVID-19 patients, PLoS ONE, doi:10.1371/journal.pone.0276751.
43.
Saha (B) et al., Manipulation of Spray-Drying Conditions to Develop an Inhalable Ivermectin Dry Powder, Pharmaceutics, doi:10.3390/pharmaceutics14071432.
44.
Jitobaom (B) et al., Synergistic anti-SARS-CoV-2 activity of repurposed anti-parasitic drug combinations, BMC Pharmacology and Toxicology, doi:10.1186/s40360-022-00580-8.
45.
Croci et al., Liposomal Systems as Nanocarriers for the Antiviral Agent Ivermectin, International Journal of Biomaterials, doi:10.1155/2016/8043983.
46.
Zheng et al., Red blood cell-hitchhiking mediated pulmonary delivery of ivermectin: Effects of nanoparticle properties, International Journal of Pharmaceutics, doi:10.1016/j.ijpharm.2022.121719.
47.
Delandre et al., Antiviral Activity of Repurposing Ivermectin against a Panel of 30 Clinical SARS-CoV-2 Strains Belonging to 14 Variants, Pharmaceuticals, doi:10.3390/ph15040445.
48.
Liu (B) et al., Genome-wide analyses reveal the detrimental impacts of SARS-CoV-2 viral gene Orf9c on human pluripotent stem cell-derived cardiomyocytes, Stem Cell Reports, doi:10.1016/j.stemcr.2022.01.014.
49.
Segatori et al., Effect of Ivermectin and Atorvastatin on Nuclear Localization of Importin Alpha and Drug Target Expression Profiling in Host Cells from Nasopharyngeal Swabs of SARS-CoV-2- Positive Patients, Viruses, doi:10.3390/v13102084.
50.
Jitobaom (C) et al., Favipiravir and Ivermectin Showed in Vitro Synergistic Antiviral Activity against SARS-CoV-2, Research Square, doi:10.21203/rs.3.rs-941811/v1.
51.
Munson et al., Niclosamide and ivermectin modulate caspase-1 activity and proinflammatory cytokine secretion in a monocytic cell line, British Society For Nanomedicine Early Career Researcher Summer Meeting, 2021, web.archive.org/web/20230401070026/https://michealmunson.github.io/COVID.pdf.
52.
Mountain Valley MD, Mountain Valley MD Receives Successful Results From BSL-4 COVID-19 Clearance Trial on Three Variants Tested With Ivectosol™, www.globenewswire.com/en/news-release/2021/05/18/2231755/0/en/Mountain-Valley-MD-Receives-Successful-Results-From-BSL-4-COVID-19-Clearance-Trial-on-Three-Variants-Tested-With-Ivectosol.html.
53.
Yesilbag et al., Ivermectin also inhibits the replication of bovine respiratory viruses (BRSV, BPIV-3, BoHV-1, BCoV and BVDV) in vitro, Virus Research, doi:10.1016/j.virusres.2021.198384.
54.
Mody et al., Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents, Communications Biology, doi:10.1038/s42003-020-01577-x.
55.
Jeffreys et al., Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2, International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2022.106542.
56.
Surnar et al., Clinically Approved Antiviral Drug in an Orally Administrable Nanoparticle for COVID-19, ACS Pharmacol. Transl. Sci., doi:10.1021/acsptsci.0c00179.
57.
Li et al., Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment, J. Cellular Physiology, doi:10.1002/jcp.30055.
58.
Caly et al., The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Research, doi:10.1016/j.antiviral.2020.104787.
59.
Zhang et al., Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice, Inflammation Research, doi:10.1007/s00011-008-8007-8.
60.
Gao et al., Ivermectin ameliorates acute myocarditis via the inhibition of importin-mediated nuclear translocation of NF-κB/p65, International Immunopharmacology, doi:10.1016/j.intimp.2024.112073.
61.
Abd-Elmawla et al., Suppression of NLRP3 inflammasome by ivermectin ameliorates bleomycin-induced pulmonary fibrosis, Journal of Zhejiang University-SCIENCE B, doi:10.1631/jzus.B2200385.
62.
Uematsu et al., Prophylactic administration of ivermectin attenuates SARS-CoV-2 induced disease in a Syrian Hamster Model, The Journal of Antibiotics, doi:10.1038/s41429-023-00623-0.
63.
Albariqi et al., Pharmacokinetics and Safety of Inhaled Ivermectin in Mice as a Potential COVID-19 Treatment, International Journal of Pharmaceutics, doi:10.1016/j.ijpharm.2022.121688.
64.
Errecalde et al., Safety and Pharmacokinetic Assessments of a Novel Ivermectin Nasal Spray Formulation in a Pig Model, Journal of Pharmaceutical Sciences, doi:10.1016/j.xphs.2021.01.017.
65.
Madrid et al., Safety of oral administration of high doses of ivermectin by means of biocompatible polyelectrolytes formulation, Heliyon, doi:10.1016/j.heliyon.2020.e05820.
66.
Ma et al., Ivermectin contributes to attenuating the severity of acute lung injury in mice, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113706.
67.
de Melo et al., Attenuation of clinical and immunological outcomes during SARS-CoV-2 infection by ivermectin, EMBO Mol. Med., doi:10.15252/emmm.202114122.
68.
Arévalo et al., Ivermectin reduces in vivo coronavirus infection in a mouse experimental model, Scientific Reports, doi:10.1038/s41598-021-86679-0.
69.
Chaccour et al., Nebulized ivermectin for COVID-19 and other respiratory diseases, a proof of concept, dose-ranging study in rats, Scientific Reports, doi:10.1038/s41598-020-74084-y.
70.
Yan et al., Anti-inflammatory effects of ivermectin in mouse model of allergic asthma, Inflammation Research, doi:10.1007/s00011-011-0307-8.
71.
Götz et al., Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import, Scientific Reports, doi:10.1038/srep23138.
72.
Tay et al., Nuclear localization of dengue virus (DENV) 1–4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin, Antiviral Research, doi:10.1016/j.antiviral.2013.06.002.
73.
Wagstaff et al., Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus, Biochemical Journal, doi:10.1042/BJ20120150.
74.
Wagstaff (B) et al., An AlphaScreen®-Based Assay for High-Throughput Screening for Specific Inhibitors of Nuclear Import, SLAS Discovery, doi:10.1177/1087057110390360.
75.
Barrows et al., A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection, Cell Host & Microbe, doi:10.1016/j.chom.2016.07.004.
76.
Yang et al., The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer, Antiviral Research, doi:10.1016/j.antiviral.2020.104760.
77.
Mastrangelo et al., Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug, Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dks147.
78.
Varghese et al., Discovery of berberine, abamectin and ivermectin as antivirals against chikungunya and other alphaviruses, Antiviral Research, doi:10.1016/j.antiviral.2015.12.012.
79.
Bennett et al., Role of a nuclear localization signal on the minor capsid Proteins VP2 and VP3 in BKPyV nuclear entry, Virology, doi:10.1016/j.virol.2014.10.013.
80.
Kosyna et al., The importin α/β-specific inhibitor Ivermectin affects HIF-dependent hypoxia response pathways, Biological Chemistry, doi:10.1515/hsz-2015-0171.
81.
Scheim et al., Sialylated Glycan Bindings from SARS-CoV-2 Spike Protein to Blood and Endothelial Cells Govern the Severe Morbidities of COVID-19, International Journal of Molecular Sciences, doi:10.3390/ijms242317039.
82.
Liu (C) et al., Crosstalk between neutrophil extracellular traps and immune regulation: insights into pathobiology and therapeutic implications of transfusion-related acute lung injury, Frontiers in Immunology, doi:10.3389/fimmu.2023.1324021.
83.
Shouman et al., SARS-CoV-2-associated lymphopenia: possible mechanisms and the role of CD147, Cell Communication and Signaling, doi:10.1186/s12964-024-01718-3.
84.
Scheim (B), D., Ivermectin for COVID-19 Treatment: Clinical Response at Quasi-Threshold Doses Via Hypothesized Alleviation of CD147-Mediated Vascular Occlusion, SSRN, doi:10.2139/ssrn.3636557.
85.
Scheim (C), D., From Cold to Killer: How SARS-CoV-2 Evolved without Hemagglutinin Esterase to Agglutinate and Then Clot Blood Cells, Center for Open Science, doi:10.31219/osf.io/sgdj2.
86.
Behl et al., CD147-spike protein interaction in COVID-19: Get the ball rolling with a novel receptor and therapeutic target, Science of The Total Environment, doi:10.1016/j.scitotenv.2021.152072.
87.
DiNicolantonio et al., Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19, Open Heart, doi:10.1136/openhrt-2020-001350.
88.
Mothae et al., SARS-CoV-2 host-pathogen interactome: insights into more players during pathogenesis, Virology, doi:10.1016/j.virol.2025.110607.
89.
Hazan et al., Treatment with Ivermectin Increases the Population of Bifidobacterium in the Gut, ACG 2023, acg2023posters.eventscribe.net/posterspeakers.asp.
Boschi et al., 28 Nov 2022, France, preprint, 8 authors.
Contact: dscheim@alum.mit.edu (corresponding author), bernard.la-scola@univamu.fr.
In vitro studies are an important part of preclinical research, however results may be very different in vivo.
SARS-CoV-2 Spike Protein Induces Hemagglutination: Implications for COVID-19 Morbidities and Therapeutics and for Vaccine Adverse Effects
doi:10.1101/2022.11.24.517882
Experimental findings for SARS-CoV-2 related to the glycan biochemistry of coronaviruses indicate that attachments from spike protein to glycoconjugates on the surfaces of red blood cells (RBCs), other blood cells and endothelial cells are key to the infectivity and morbidity of COVID-19. To provide further insight into these glycan attachments and their potential clinical relevance, the classic hemagglutination (HA) assay was applied using spike protein from the Wuhan, Alpha, Delta and Omicron B.1.1.529 lineages of SARS-CoV-2 mixed with human RBCs. The electrostatic potential of the central region of spike protein from these four lineages was studied through molecular modeling simulations. Inhibition of spike protein-induced HA was tested using the macrocyclic lactone ivermectin (IVM), which is indicated to bind strongly to SARS-CoV-2 spike protein glycan sites. The results of these experiments were, first, that spike protein from these four lineages of SARS-CoV-2 induced HA. Omicron induced HA at a significantly lower threshold concentration of spike protein than for the three prior lineages and was much more electropositive on its central spike protein region. IVM blocked HA when added to RBCs prior to spike protein and reversed HA when added afterwards. These results validate and extend prior findings on the role of glycan bindings of viral spike protein in COVID-19. They furthermore suggest therapeutic options using competitive glycan-binding agents such as IVM and may help elucidate rare serious adverse effects (AEs) associated with COVID-19 mRNA vaccines which use spike protein as the generated antigen.
References
Ahmetaj-Shala, Vaja, Atanur, George, Kirkby et al., Cardiorenal Tissues Express SARS-CoV-2 Entry Genes and Basigin (BSG/CD147) Increases With Age in Endothelial Cells, JACC: Basic to Translational Science
Aminpour, Cannariato, Safaeeardebili, Preto, Moracchiato et al., Silico Analysis of the Multi-Targeted Mode of Action of Ivermectin and Related Compounds, Computation
Aoki, A Comprehensive Review of Our Current Understanding of Red Blood Cell (RBC) Glycoproteins, Membranes
Au Sam, Storey Brian, Moore John, Tang, Chen et al., Clusters of circulating tumor cells traverse capillary-sized vessels, Proceedings of the National Academy of Sciences
Back, Kostova, Klei, Beuger, Van Zwieten et al., RBC Adhesive Capacity Is Essential for Efficient 'Immune Adherence Clearance' and Provide a Generic Target to Deplete Pathogens from Septic Patients, Blood
Baker, Richards, Guy, Congdon, Hasan et al., The SARS-COV-2 Spike Protein Binds Sialic Acids and Enables Rapid Detection in a Lateral Flow Point of Care Diagnostic Device, ACS Central Science
Barshtein, Wajnblum, Yedgar, Kinetics of linear rouleaux formation studied by visual monitoring of red cell dynamic organization, Biophys J
Baum, Ward, Conway, Natural selection on the erythrocyte surface, Mol Biol Evol
Becker, COVID-19 update: Covid-19-associated coagulopathy, J Thromb Thrombolysis
Berzuini, Bianco, Migliorini, Maggioni, Valenti et al., Red blood cell morphology in patients with COVID-19-related anaemia, Blood Transfus
Biancatelli, Solopov, Sharlow, Lazo, Marik et al., The SARS-CoV-2 spike protein subunit S1 induces COVID-19-like acute lung injury in Κ18-hACE2 transgenic mice and barrier dysfunction in human endothelial cells, Am J Physiol Lung Cell Mol Physiol
Boschi, Colson, Bancod, Moal, La Scola, Omicron Variant Escapes Therapeutic Monoclonal Antibodies (mAbs) Including Recently Released Evusheld®, Contrary to 8 Prior Main Variant of Concern (VOC), Clinical Infectious Diseases
Boulant, Stanifer, Lozach, Dynamics of virus-receptor interactions in virus binding, signaling, and endocytosis, Viruses
Callebaut, Pensaert, Characterization and isolation of structural polypeptides in haemagglutinating encephalomyelitis virus, J Gen Virol
Chen, Hui, Ren, Luo, Shu et al., The N-glycosylation sites and Glycan-binding ability of S-protein in SARS-CoV-2 Coronavirus, bioRxiv, doi:10.1101/2020.12.01.406025
Choi, Cao, Frank, Woo, Park et al., Structure, Dynamics, Receptor Binding, and Antibody Binding of the Fully Glycosylated Full-Length SARS-CoV-2 Spike Protein in a Viral Membrane, Journal of Chemical Theory and Computation
Cognetti, Miller, Monitoring Serum Spike Protein with Disposable Photonic Biosensors Following SARS-CoV-2 Vaccination, Sensors
Colson, Levasseur, Delerce, Pinault, Dudouet et al., Spreading of a new SARS-CoV-2 N501Y spike variant in a new lineage, Clin Microbiol Infect
Cosentino, Marino, The spike hypothesis in vaccine-induced adverse effects: questions and answers, Trends in Molecular Medicine
Doria, Santin, Tuszynski, Scheim, Aminpour, Omicron SARS-CoV-2 Spike-1 Protein's Decreased Binding Affinity to α7nAChr: Implications for Autonomic Dysregulation of the Parasympathetic Nervous System and the Cholinergic Anti-Inflammatory Pathway-An In Silico Analysis, BioMedInformatics
Fantini, Di Scala, Chahinian, Yahi, Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection, International Journal of Antimicrobial Agents
Fantini, Yahi, Azzaz, Chahinian, Structural dynamics of SARS-CoV-2 variants: A health monitoring strategy for anticipating Covid-19 outbreaks, J Infect
Fantini, Yahi, Colson, Chahinian, La Scola et al., The puzzling mutational landscape of the SARS-2-variant Omicron, Journal of Medical Virology
Gao, Zeng, Jia, Stavenhagen, Matsumoto et al., SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors, bioRxiv, doi:10.1101/2020.07.29.227462
Gattinoni, Coppola, Cressoni, Busana, Rossi et al., COVID-19 Does Not Lead to a "Typical" Acute Respiratory Distress Syndrome, Am J Respir Crit Care Med
Giovannini, Dark Field Microscopic Analysis on the Blood of 1,006 Symptomatic Persons After Anti-COVID mRNA Injections from Pfizer/BioNTech or Moderna, International Journal of Vaccine Theory, Practice, and Research
Grobbelaar, Venter, Vlok, Ngoepe, Laubscher et al., SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: implications for microclot formation in COVID-19, Bioscience Reports
Guex, Peitsch, SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling, Electrophoresis
Guo, Lakshminarayanan, Rodriguez-Palacios, Salata, Xu et al., Glycan Nanostructures of Human Coronaviruses, Int J Nanomedicine
Gupta, Maciorowski, Zak, Kulkarni, Herbert et al., Heparin: A simplistic repurposing to prevent SARS-CoV-2 transmission in light of its in-vitro nanomolar efficacy, Int J Biol Macromol
Hao, Ma, Li, Wang, Gao et al., Binding of the SARS-CoV-2 spike protein to glycans, Sci Bull
Hassanzadeh, Perez Pena, Dragotto, Buccarello, Iorio et al., Considerations around the SARS-CoV-2 Spike Protein with Particular Attention to COVID-19 Brain Infection and Neurological Symptoms, ACS Chem Neurosci
Huertas, Montani, Savale, Pichon, Tu et al., Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)?, Eur Respir J
Jaafar, Boschi, Aherfi, Bancod, Le Bideau et al., High Individual Heterogeneity of Neutralizing Activities against the Original Strain and Nine Different Variants of SARS-CoV-2, Viruses, doi:10.3390/v13112177
Karim, Devnarain, Time to Stop Using Ineffective Covid-19 Drugs, N Engl J Med
Kim, Chivian, Baker, Protein structure prediction and analysis using the Robetta server, Nucleic Acids Res
Klotz, Ogbuokiri, Okonkwo, Ivermectin binds avidly to plasma proteins, Eur J Clin Pharmacol
Koehler, Delguste, Sieben, Gillet, Alsteens, Initial Step of Virus Entry: Virion Binding to Cell-Surface Glycans, Annual Review of Virology
Kumar, Karuppanan, Subramaniam, Omicron, BA.1) and sub-variants (BA.1.1, BA.2, and BA.3) of SARS-CoV-2 spike infectivity and pathogenicity: A comparative sequence and structural-based computational assessment, Journal of Medical Virology
Lakhdari, Tabet, Boudraham, Laoussati, Aissanou et al., Red blood cells injuries and hypersegmented neutrophils in COVID-19 peripheral blood film, medRxiv, doi:10.1101/2020.07.24.20160101
Lam, Murphy, Kuri-Cervantes, Weisman, Ittner et al., Erythrocytes Reveal Complement Activation in Patients with COVID-19, medRxiv, doi:10.1101/2020.05.20.20104398
Lam, Waman, Orengo, Lees, Insertions in the SARS-CoV-2 Spike N-Terminal Domain May Aid COVID-19 Transmission, bioRxiv, doi:10.1101/2021.12.06.471394
Lang, Li, Li, Koerhuis, Van Den Burg et al., Coronavirus hemagglutinin-esterase and spike proteins coevolve for functional balance and optimal virion avidity, Proc Natl Acad Sci
Li, Chen, Zhao, Lung, Ye et al., Intravenous Injection of Coronavirus Disease 2019 (COVID-19) mRNA Vaccine Can Induce Acute Myopericarditis in Mouse Model, Clinical Infectious Diseases
Maeda, Seike, Kon, Shiga, Erythrocyte Aggregation as a Determinant of Blood Flow: Effect of pH, Temperature and Osmotic Pressure, doi:10.1007/978-1-4615-9510-6_68pp.563-570
Magro, Mulvey, Berlin, Nuovo, Salvatore et al., Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases, Transl Res
Mansanguan, Charunwatthana, Piyaphanee, Dechkhajorn, Poolcharoen et al., Cardiovascular Manifestation of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents, Tropical Medicine and Infectious Disease
Marini, Gattinoni, Management of COVID-19 Respiratory Distress, JAMA
Maslo, Friedland, Toubkin, Laubscher, Akaloo et al., Characteristics and Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave Compared With Previous Waves, JAMA
Melkumyants, Buryachkovskaya, Lomakin, Antonova, Serebruany, Mild COVID-19 and Impaired Blood Cell-Endothelial Crosstalk: Considering Long-Term Use of Antithrombotics?, Thromb Haemost
Menter, Haslbauer, Nienhold, Savic, Hopfer et al., Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction, Histopathology
Morniroli, Giannì, Consales, Pietrasanta, Mosca, Human Sialome and Coronavirus Disease-2019 (COVID-19) Pandemic: An Understated Correlation?, Frontiers in Immunology
Neu, Bauer, Stehle, Viruses and sialic acids: rules of engagement, Curr Opin Struct Biol
Nguyen, Mccord, Bui, Bouwman, Kitova et al., Sialic acid-containing glycolipids mediate binding and viral entry of SARS-CoV-2, Nature Chemical Biology
Nuovo, Magro, Shaffer, Awad, Suster et al., Endothelial cell damage is the central part of COVID-19 and a mouse model induced by injection of the S1 subunit of the spike protein, Annals of Diagnostic Pathology
Ogata, Cheng, Desjardins, Senussi, Sherman et al., Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients, Clin Infect Dis
Pascarella, Ciccozzi, Bianchi, Benvenuto, Cauda et al., The value of electrostatic potentials of the spike receptor binding and N-terminal domains in addressing transmissibility and infectivity of SARS-CoV-2 variants of concern, J Infect
Pawłowski, Additional Positive Electric Residues in the Crucial Spike Glycoprotein S Regions of the New SARS-CoV-2 Variants, Infect Drug Resist
Perico, Morigi, Galbusera, Pezzotta, Gastoldi et al., SARS-CoV-2 Spike Protein 1 Activates Microvascular Endothelial Cells and Complement System Leading to Platelet Aggregation, Front Immunol
Price, Mccabe, Garfield, Wort, Thrombosis and COVID-19 pneumonia: the clot thickens!, European Respiratory Journal
Rambaut, Holmes, O'toole, Hill, Mccrone et al., A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology, Nature Microbiology
Röltgen, Nielsen, Silva, Younes, Zaslavsky et al., Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination, Cell
Santin, Scheim, Mccullough, Yagisawa, Borody, Ivermectin: a multifaceted drug of Nobel prize-honored distinction with indicated efficacy against a new global scourge, COVID-19, New Microbes and New Infections
Scheim, A Deadly Embrace: Hemagglutination Mediated by SARS-CoV-2 Spike Protein at its 22 N-Glycosylation Sites, Red Blood Cell Surface Sialoglycoproteins, and Antibody, Int. J. Mol. Sci
Scheim, From cold to killer: How SARS-CoV-2 evolved without hemagglutinin esterase to agglutinate, then clot blood cells in pulmonary and systemic microvasculature
Schultze, Gross, Brossmer, Herrler, The S protein of bovine coronavirus is a hemagglutinin recognizing 9-O-acetylated sialic acid as a receptor determinant, J Virol
Seaman, Electrochemical features of platelet interactions, Thrombosis Research
Shafiee, Teymouri Athar, Kohandel Gargari, Jafarabady, Siahvoshi et al., Ivermectin under scrutiny: a systematic review and meta-analysis of efficacy and possible sources of controversies in COVID-19 patients, Virology Journal
Shajahan, Supekar, Gleinich, Azadi, Deducing the N-and O-glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2, Glycobiology
Shilts, Wright, No evidence for basigin/CD147 as a direct SARS-CoV-2 spike binding receptor, bioRxiv, doi:10.1101/2020.07.25.221036
Sikora, Von Bülow, Blanc, Gecht, Covino et al., Computational epitope map of SARS-CoV-2 spike protein, PLOS Computational Biology
Stone, Ndarukwa, Scheim, Dancis, Dancis et al., Changes in SpO2 on Room Air for 34 Severe COVID-19 Patients after Ivermectin-Based Combination Treatment: 62% Normalization within 24 Hours, Biologics
Strilić, Eglinger, Krieg, Zeeb, Axnick et al., Electrostatic Cell-Surface Repulsion Initiates Lumen Formation in Developing Blood Vessels, Current Biology
Ströh, Stehle, Glycan Engagement by Viruses: Receptor Switches and Specificity, Annual Review of Virology
Townsend, Rijal, Xiao, Tan, Huang et al., A haemagglutination test for rapid detection of antibodies to SARS-CoV-2, Nat Commun
Trougakos, Terpos, Alexopoulos, Politou, Paraskevis et al., Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis, Trends in Molecular Medicine
Varki, Gagneux, Multifarious roles of sialic acids in immunity, Ann N Y Acad Sci
Yagisawa, Omura, None
Yamakawa, Vanbeselaere, Chang, Yu, Ducrocq et al., Systems glycomics of adult zebrafish identifies organ-specific sialylation and glycosylation patterns, Nature Communications
Zheng, Zhao, Li, Guo, Sheng et al., SARS-CoV-2 spike protein causes blood coagulation and thrombosis by competitive binding to heparan sulfate, Int J Biol Macromol
DOI record:
{
"DOI": "10.1101/2022.11.24.517882",
"URL": "http://dx.doi.org/10.1101/2022.11.24.517882",
"abstract": "<jats:title>ABSTRACT</jats:title><jats:p>Experimental findings for SARS-CoV-2 related to the glycan biochemistry of coronaviruses indicate that attachments from spike protein to glycoconjugates on the surfaces of red blood cells (RBCs), other blood cells and endothelial cells are key to the infectivity and morbidity of COVID-19. To provide further insight into these glycan attachments and their potential clinical relevance, the classic hemagglutination (HA) assay was applied using spike protein from the Wuhan, Alpha, Delta and Omicron B.1.1.529 lineages of SARS-CoV-2 mixed with human RBCs. The electrostatic potential of the central region of spike protein from these four lineages was studied through molecular modeling simulations. Inhibition of spike protein-induced HA was tested using the macrocyclic lactone ivermectin (IVM), which is indicated to bind strongly to SARS-CoV-2 spike protein glycan sites. The results of these experiments were, first, that spike protein from these four lineages of SARS-CoV-2 induced HA. Omicron induced HA at a significantly lower threshold concentration of spike protein than for the three prior lineages and was much more electropositive on its central spike protein region. IVM blocked HA when added to RBCs prior to spike protein and reversed HA when added afterwards. These results validate and extend prior findings on the role of glycan bindings of viral spike protein in COVID-19. They furthermore suggest therapeutic options using competitive glycan-binding agents such as IVM and may help elucidate rare serious adverse effects (AEs) associated with COVID-19 mRNA vaccines which use spike protein as the generated antigen.</jats:p>",
"accepted": {
"date-parts": [
[
2022,
11,
28
]
]
},
"author": [
{
"ORCID": "http://orcid.org/0000-0003-2504-7828",
"affiliation": [],
"authenticated-orcid": false,
"family": "Boschi",
"given": "Celine",
"sequence": "first"
},
{
"ORCID": "http://orcid.org/0000-0001-6841-7054",
"affiliation": [],
"authenticated-orcid": false,
"family": "Scheim",
"given": "David E.",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0001-6832-5897",
"affiliation": [],
"authenticated-orcid": false,
"family": "Bancod",
"given": "Audrey",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Millitello",
"given": "Muriel",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Bideau",
"given": "Marion Le",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0001-6285-0308",
"affiliation": [],
"authenticated-orcid": false,
"family": "Colson",
"given": "Philippe",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0001-8653-5521",
"affiliation": [],
"authenticated-orcid": false,
"family": "Fantini",
"given": "Jacques",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0001-8006-7704",
"affiliation": [],
"authenticated-orcid": false,
"family": "Scola",
"given": "Bernard La",
"sequence": "additional"
}
],
"container-title": [],
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2022,
11,
29
]
],
"date-time": "2022-11-29T02:19:39Z",
"timestamp": 1669688379000
},
"deposited": {
"date-parts": [
[
2022,
11,
29
]
],
"date-time": "2022-11-29T21:53:26Z",
"timestamp": 1669758806000
},
"group-title": "Biochemistry",
"indexed": {
"date-parts": [
[
2022,
11,
30
]
],
"date-time": "2022-11-30T05:59:45Z",
"timestamp": 1669787985037
},
"institution": [
{
"name": "bioRxiv"
}
],
"is-referenced-by-count": 0,
"issued": {
"date-parts": [
[
2022,
11,
28
]
]
},
"link": [
{
"URL": "https://syndication.highwire.org/content/doi/10.1101/2022.11.24.517882",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "246",
"original-title": [],
"posted": {
"date-parts": [
[
2022,
11,
28
]
]
},
"prefix": "10.1101",
"published": {
"date-parts": [
[
2022,
11,
28
]
]
},
"publisher": "Cold Spring Harbor Laboratory",
"reference": [
{
"DOI": "10.3390/ijms23052558",
"article-title": "A Deadly Embrace: Hemagglutination Mediated by SARS-CoV-2 Spike Protein at its 22 N-Glycosylation Sites, Red Blood Cell Surface Sialoglycoproteins, and Antibody",
"doi-asserted-by": "crossref",
"first-page": "2558",
"journal-title": "Int. J. Mol. Sci",
"key": "2022112911400656000_2022.11.24.517882v1.1",
"volume": "23",
"year": "2022"
},
{
"DOI": "10.1101/2020.12.01.406025",
"doi-asserted-by": "publisher",
"key": "2022112911400656000_2022.11.24.517882v1.2"
},
{
"DOI": "10.2147/IJN.S302516",
"article-title": "Glycan Nanostructures of Human Coronaviruses",
"doi-asserted-by": "crossref",
"first-page": "4813",
"journal-title": "Int J Nanomedicine",
"key": "2022112911400656000_2022.11.24.517882v1.3",
"volume": "16",
"year": "2021"
},
{
"DOI": "10.1093/glycob/cwaa042",
"article-title": "Deducing the N- and O-glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2",
"doi-asserted-by": "crossref",
"first-page": "981",
"journal-title": "Glycobiology",
"key": "2022112911400656000_2022.11.24.517882v1.4",
"volume": "30",
"year": "2020"
},
{
"DOI": "10.1101/2020.07.29.227462",
"doi-asserted-by": "publisher",
"key": "2022112911400656000_2022.11.24.517882v1.5"
},
{
"DOI": "10.1371/journal.pcbi.1008790",
"article-title": "Computational epitope map of SARS-CoV-2 spike protein",
"doi-asserted-by": "crossref",
"first-page": "e1008790",
"journal-title": "PLOS Computational Biology",
"key": "2022112911400656000_2022.11.24.517882v1.6",
"volume": "17",
"year": "2021"
},
{
"DOI": "10.1021/acs.jctc.0c01144",
"article-title": "Structure, Dynamics, Receptor Binding, and Antibody Binding of the Fully Glycosylated Full-Length SARS-CoV-2 Spike Protein in a Viral Membrane",
"doi-asserted-by": "crossref",
"first-page": "2479",
"journal-title": "Journal of Chemical Theory and Computation",
"key": "2022112911400656000_2022.11.24.517882v1.7",
"volume": "17",
"year": "2021"
},
{
"DOI": "10.1146/annurev-virology-122019-070025",
"article-title": "Initial Step of Virus Entry: Virion Binding to Cell-Surface Glycans",
"doi-asserted-by": "crossref",
"first-page": "143",
"journal-title": "Annual Review of Virology",
"key": "2022112911400656000_2022.11.24.517882v1.8",
"volume": "7",
"year": "2020"
},
{
"DOI": "10.1016/j.ijantimicag.2020.105960",
"doi-asserted-by": "publisher",
"key": "2022112911400656000_2022.11.24.517882v1.9"
},
{
"DOI": "10.1146/annurev-virology-031413-085417",
"article-title": "Glycan Engagement by Viruses: Receptor Switches and Specificity",
"doi-asserted-by": "crossref",
"first-page": "285",
"journal-title": "Annual Review of Virology",
"key": "2022112911400656000_2022.11.24.517882v1.10",
"volume": "1",
"year": "2014"
},
{
"DOI": "10.3389/fimmu.2020.01480",
"article-title": "Human Sialome and Coronavirus Disease-2019 (COVID-19) Pandemic: An Understated Correlation?",
"doi-asserted-by": "crossref",
"first-page": "1480",
"journal-title": "Frontiers in Immunology",
"key": "2022112911400656000_2022.11.24.517882v1.11",
"volume": "11",
"year": "2020"
},
{
"DOI": "10.1016/j.sbi.2011.08.009",
"doi-asserted-by": "publisher",
"key": "2022112911400656000_2022.11.24.517882v1.12"
},
{
"DOI": "10.1038/s41589-021-00924-1",
"article-title": "Sialic acid-containing glycolipids mediate binding and viral entry of SARS-CoV-2",
"doi-asserted-by": "crossref",
"first-page": "81",
"journal-title": "Nature Chemical Biology",
"key": "2022112911400656000_2022.11.24.517882v1.13",
"volume": "18",
"year": "2022"
},
{
"DOI": "10.1093/oxfordjournals.molbev.a004075",
"doi-asserted-by": "publisher",
"key": "2022112911400656000_2022.11.24.517882v1.14"
},
{
"DOI": "10.3390/membranes7040056",
"doi-asserted-by": "crossref",
"key": "2022112911400656000_2022.11.24.517882v1.15",
"unstructured": "Aoki, T. A Comprehensive Review of Our Current Understanding of Red Blood Cell (RBC) Glycoproteins. Membranes (Basel) 2017, 7."
},
{
"DOI": "10.1016/0049-3848(76)90066-9",
"article-title": "Electrochemical features of platelet interactions",
"doi-asserted-by": "crossref",
"first-page": "235",
"journal-title": "Thrombosis Research",
"key": "2022112911400656000_2022.11.24.517882v1.16",
"volume": "8",
"year": "1976"
},
{
"DOI": "10.1016/j.cub.2010.09.061",
"doi-asserted-by": "publisher",
"key": "2022112911400656000_2022.11.24.517882v1.17"
},
{
"DOI": "10.3390/v7062747",
"doi-asserted-by": "publisher",
"key": "2022112911400656000_2022.11.24.517882v1.18"
},
{
"DOI": "10.1021/acschemneuro.0c00373",
"doi-asserted-by": "publisher",
"key": "2022112911400656000_2022.11.24.517882v1.19"
},
{
"DOI": "10.2147/IDR.S342068",
"doi-asserted-by": "publisher",
"key": "2022112911400656000_2022.11.24.517882v1.20"
},
{
"article-title": "Cardiorenal Tissues Express SARS-CoV-2 Entry Genes and Basigin (BSG/CD147) Increases With Age in Endothelial Cells",
"first-page": "1111",
"journal-title": "JACC: Basic to Translational Science",
"key": "2022112911400656000_2022.11.24.517882v1.21",
"volume": "5",
"year": "2020"
},
{
"DOI": "10.1183/13993003.01634-2020",
"doi-asserted-by": "crossref",
"key": "2022112911400656000_2022.11.24.517882v1.22",
"unstructured": "Huertas, A. ; Montani, D. ; Savale, L. ; Pichon, J. ; Tu, L. ; Parent, F. ; Guignabert, C. ; Humbert, M. Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)? Eur Respir J 2020, 56."
},
{
"DOI": "10.31219/osf.io/sgdj2",
"doi-asserted-by": "crossref",
"key": "2022112911400656000_2022.11.24.517882v1.23",
"unstructured": "Scheim, D.E. From cold to killer: How SARS-CoV-2 evolved without hemagglutinin esterase to agglutinate, then clot blood cells in pulmonary and systemic microvasculature. Available online: https://osf.io/sgdj2 (accessed on October 17, 2022)."
},
{
"DOI": "10.1182/blood.V128.22.1031.1031",
"article-title": "RBC Adhesive Capacity Is Essential for Efficient ‘Immune Adherence Clearance’ and Provide a Generic Target to Deplete Pathogens from Septic Patients",
"doi-asserted-by": "crossref",
"first-page": "1031",
"journal-title": "Blood",
"key": "2022112911400656000_2022.11.24.517882v1.24",
"volume": "128",
"year": "2016"
},
{
"DOI": "10.1111/j.1749-6632.2012.06517.x",
"doi-asserted-by": "publisher",
"key": "2022112911400656000_2022.11.24.517882v1.25"
},
{
"article-title": "Red blood cell morphology in patients with COVID-19-related anaemia",
"first-page": "34",
"journal-title": "Blood Transfus",
"key": "2022112911400656000_2022.11.24.517882v1.26",
"volume": "19",
"year": "2021"
},
{
"DOI": "10.1055/a-1551-9911",
"article-title": "Mild COVID-19 and Impaired Blood Cell–Endothelial Crosstalk: Considering Long-Term Use of Antithrombotics?",
"doi-asserted-by": "crossref",
"first-page": "123",
"journal-title": "Thromb Haemost",
"key": "2022112911400656000_2022.11.24.517882v1.27",
"volume": "122",
"year": "2022"
},
{
"DOI": "10.1101/2020.07.24.20160101",
"doi-asserted-by": "publisher",
"key": "2022112911400656000_2022.11.24.517882v1.28"
},
{
"DOI": "10.1101/2020.05.20.20104398",
"doi-asserted-by": "publisher",
"key": "2022112911400656000_2022.11.24.517882v1.29"
},
{
"DOI": "10.1021/acscentsci.0c00855",
"article-title": "The SARS-COV-2 Spike Protein Binds Sialic Acids and Enables Rapid Detection in a Lateral Flow Point of Care Diagnostic Device",
"doi-asserted-by": "crossref",
"first-page": "2046",
"journal-title": "ACS Central Science",
"key": "2022112911400656000_2022.11.24.517882v1.30",
"volume": "6",
"year": "2020"
},
{
"DOI": "10.1016/j.scib.2021.01.010",
"article-title": "Binding of the SARS-CoV-2 spike protein to glycans",
"doi-asserted-by": "crossref",
"first-page": "1205",
"journal-title": "Sci Bull (Beijing)",
"key": "2022112911400656000_2022.11.24.517882v1.31",
"volume": "66",
"year": "2021"
},
{
"DOI": "10.1101/2020.07.25.221036",
"doi-asserted-by": "publisher",
"key": "2022112911400656000_2022.11.24.517882v1.32"
},
{
"DOI": "10.1007/978-1-4615-9510-6_68",
"doi-asserted-by": "publisher",
"key": "2022112911400656000_2022.11.24.517882v1.33"
},
{
"DOI": "10.1016/S0006-3495(00)76791-9",
"doi-asserted-by": "publisher",
"key": "2022112911400656000_2022.11.24.517882v1.34"
},
{
"DOI": "10.1016/j.trsl.2020.04.007",
"doi-asserted-by": "publisher",
"key": "2022112911400656000_2022.11.24.517882v1.35"
},
{
"DOI": "10.1111/his.14134",
"article-title": "Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction",
"doi-asserted-by": "crossref",
"first-page": "198",
"journal-title": "Histopathology",
"key": "2022112911400656000_2022.11.24.517882v1.36",
"volume": "77",
"year": "2020"
},
{
"DOI": "10.1007/s11239-020-02134-3",
"article-title": "COVID-19 update: Covid-19-associated coagulopathy",
"doi-asserted-by": "crossref",
"first-page": "54",
"journal-title": "J Thromb Thrombolysis",
"key": "2022112911400656000_2022.11.24.517882v1.37",
"volume": "50",
"year": "2020"
},
{
"DOI": "10.1164/rccm.202003-0817LE",
"doi-asserted-by": "publisher",
"key": "2022112911400656000_2022.11.24.517882v1.38"
},
{
"DOI": "10.1001/jama.2020.6825",
"article-title": "Management of COVID-19 Respiratory Distress",
"doi-asserted-by": "crossref",
"first-page": "2329",
"journal-title": "JAMA",
"key": "2022112911400656000_2022.11.24.517882v1.39",
"volume": "323",
"year": "2020"
},
{
"DOI": "10.1042/BSR20210611",
"doi-asserted-by": "crossref",
"key": "2022112911400656000_2022.11.24.517882v1.40",
"unstructured": "Grobbelaar, Lize M. ; Venter, C. ; Vlok, M. ; Ngoepe, M. ; Laubscher Gert J. ; Lourens Petrus J. ; Steenkamp, J. ; Kell Douglas B. ; Pretorius, E. SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: implications for microclot formation in COVID-19. Bioscience Reports 2021, 41."
},
{
"DOI": "10.1128/jvi.65.11.6232-6237.1991",
"article-title": "The S protein of bovine coronavirus is a hemagglutinin recognizing 9-O-acetylated sialic acid as a receptor determinant",
"doi-asserted-by": "crossref",
"first-page": "6232",
"journal-title": "J Virol",
"key": "2022112911400656000_2022.11.24.517882v1.41",
"volume": "65",
"year": "1991"
},
{
"DOI": "10.1099/0022-1317-48-1-193",
"article-title": "Characterization and isolation of structural polypeptides in haemagglutinating encephalomyelitis virus",
"doi-asserted-by": "crossref",
"first-page": "193",
"journal-title": "J Gen Virol",
"key": "2022112911400656000_2022.11.24.517882v1.42",
"volume": "48",
"year": "1980"
},
{
"DOI": "10.3390/computation10040051",
"article-title": "In Silico Analysis of the Multi-Targeted Mode of Action of Ivermectin and Related Compounds",
"doi-asserted-by": "crossref",
"first-page": "51",
"journal-title": "Computation",
"key": "2022112911400656000_2022.11.24.517882v1.43",
"volume": "10",
"year": "2022"
},
{
"DOI": "10.1016/j.nmni.2021.100924",
"article-title": "Ivermectin: a multifaceted drug of Nobel prize-honored distinction with indicated efficacy against a new global scourge, COVID-19",
"doi-asserted-by": "crossref",
"first-page": "100924",
"journal-title": "New Microbes and New Infections",
"key": "2022112911400656000_2022.11.24.517882v1.44",
"volume": "43",
"year": "2021"
},
{
"DOI": "10.1056/NEJMe2209017",
"article-title": "Time to Stop Using Ineffective Covid-19 Drugs",
"doi-asserted-by": "crossref",
"first-page": "654",
"journal-title": "N Engl J Med",
"key": "2022112911400656000_2022.11.24.517882v1.45",
"volume": "387",
"year": "2022"
},
{
"DOI": "10.1186/s12985-022-01829-8",
"article-title": "Ivermectin under scrutiny: a systematic review and meta-analysis of efficacy and possible sources of controversies in COVID-19 patients",
"doi-asserted-by": "crossref",
"first-page": "102",
"journal-title": "Virology Journal",
"key": "2022112911400656000_2022.11.24.517882v1.46",
"volume": "19",
"year": "2022"
},
{
"DOI": "10.1073/pnas.1524448113",
"doi-asserted-by": "publisher",
"key": "2022112911400656000_2022.11.24.517882v1.47"
},
{
"DOI": "10.1038/s41467-018-06950-3",
"article-title": "Systems glycomics of adult zebrafish identifies organ-specific sialylation and glycosylation patterns",
"doi-asserted-by": "crossref",
"first-page": "4647",
"journal-title": "Nature Communications",
"key": "2022112911400656000_2022.11.24.517882v1.48",
"volume": "9",
"year": "2018"
},
{
"DOI": "10.1016/j.ijbiomac.2021.10.112",
"article-title": "SARS-CoV-2 spike protein causes blood coagulation and thrombosis by competitive binding to heparan sulfate",
"doi-asserted-by": "crossref",
"first-page": "1124",
"journal-title": "Int J Biol Macromol",
"key": "2022112911400656000_2022.11.24.517882v1.49",
"volume": "193",
"year": "2021"
},
{
"DOI": "10.1152/ajplung.00223.2021",
"article-title": "The SARS-CoV-2 spike protein subunit S1 induces COVID-19-like acute lung injury in K18-hACE2 transgenic mice and barrier dysfunction in human endothelial cells",
"doi-asserted-by": "crossref",
"first-page": "L477",
"journal-title": "Am J Physiol Lung Cell Mol Physiol",
"key": "2022112911400656000_2022.11.24.517882v1.50",
"volume": "321",
"year": "2021"
},
{
"DOI": "10.1016/j.anndiagpath.2020.151682",
"article-title": "Endothelial cell damage is the central part of COVID-19 and a mouse model induced by injection of the S1 subunit of the spike protein",
"doi-asserted-by": "crossref",
"first-page": "151682",
"journal-title": "Annals of Diagnostic Pathology",
"key": "2022112911400656000_2022.11.24.517882v1.51",
"volume": "51",
"year": "2021"
},
{
"DOI": "10.3389/fimmu.2022.827146",
"doi-asserted-by": "publisher",
"key": "2022112911400656000_2022.11.24.517882v1.52"
},
{
"DOI": "10.1002/jmv.27577",
"article-title": "The puzzling mutational landscape of the SARS-2-variant Omicron",
"doi-asserted-by": "crossref",
"first-page": "2019",
"journal-title": "Journal of Medical Virology",
"key": "2022112911400656000_2022.11.24.517882v1.53",
"volume": "94",
"year": "2022"
},
{
"DOI": "10.1183/13993003.01608-2020",
"doi-asserted-by": "publisher",
"key": "2022112911400656000_2022.11.24.517882v1.54"
},
{
"DOI": "10.1001/jama.2021.24868",
"article-title": "Characteristics and Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave Compared With Previous Waves",
"doi-asserted-by": "crossref",
"first-page": "583",
"journal-title": "JAMA",
"key": "2022112911400656000_2022.11.24.517882v1.55",
"volume": "327",
"year": "2022"
},
{
"DOI": "10.1073/pnas.2006299117",
"doi-asserted-by": "publisher",
"key": "2022112911400656000_2022.11.24.517882v1.56"
},
{
"DOI": "10.1002/jmv.27927",
"article-title": "Omicron (BA.1) and sub-variants (BA.1.1, BA.2, and BA.3) of SARS-CoV-2 spike infectivity and pathogenicity: A comparative sequence and structural-based computational assessment",
"doi-asserted-by": "crossref",
"first-page": "4780",
"journal-title": "Journal of Medical Virology",
"key": "2022112911400656000_2022.11.24.517882v1.57",
"volume": "94",
"year": "2022"
},
{
"DOI": "10.1016/j.jinf.2022.02.023",
"article-title": "The value of electrostatic potentials of the spike receptor binding and N-terminal domains in addressing transmissibility and infectivity of SARS-CoV-2 variants of concern",
"doi-asserted-by": "crossref",
"first-page": "e62",
"journal-title": "J Infect",
"key": "2022112911400656000_2022.11.24.517882v1.58",
"volume": "84",
"year": "2022"
},
{
"DOI": "10.1101/2021.12.06.471394",
"doi-asserted-by": "publisher",
"key": "2022112911400656000_2022.11.24.517882v1.59"
},
{
"DOI": "10.3390/biomedinformatics2040035",
"article-title": "Omicron SARS-CoV-2 Spike-1 Protein’s Decreased Binding Affinity to α7nAChr: Implications for Autonomic Dysregulation of the Parasympathetic Nervous System and the Cholinergic Anti-Inflammatory Pathway—An In Silico Analysis",
"doi-asserted-by": "crossref",
"first-page": "553",
"journal-title": "BioMedInformatics",
"key": "2022112911400656000_2022.11.24.517882v1.60",
"volume": "2",
"year": "2022"
},
{
"key": "2022112911400656000_2022.11.24.517882v1.61",
"unstructured": "M. Yagisawa and S. Omura , personal communication (email) of November 7, 2022."
},
{
"DOI": "10.3390/biologics2030015",
"article-title": "Changes in SpO2 on Room Air for 34 Severe COVID-19 Patients after Ivermectin-Based Combination Treatment: 62% Normalization within 24 Hours",
"doi-asserted-by": "crossref",
"first-page": "196",
"journal-title": "Biologics",
"key": "2022112911400656000_2022.11.24.517882v1.62",
"volume": "2",
"year": "2022"
},
{
"DOI": "10.1016/j.ijbiomac.2021.04.148",
"article-title": "Heparin: A simplistic repurposing to prevent SARS-CoV-2 transmission in light of its in-vitro nanomolar efficacy",
"doi-asserted-by": "crossref",
"first-page": "203",
"journal-title": "Int J Biol Macromol",
"key": "2022112911400656000_2022.11.24.517882v1.63",
"volume": "183",
"year": "2021"
},
{
"DOI": "10.1093/cid/ciab707",
"article-title": "Intravenous Injection of Coronavirus Disease 2019 (COVID-19) mRNA Vaccine Can Induce Acute Myopericarditis in Mouse Model",
"doi-asserted-by": "crossref",
"first-page": "1933",
"journal-title": "Clinical Infectious Diseases",
"key": "2022112911400656000_2022.11.24.517882v1.64",
"volume": "74",
"year": "2022"
},
{
"DOI": "10.1016/j.molmed.2022.04.007",
"article-title": "Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis",
"doi-asserted-by": "crossref",
"first-page": "542",
"journal-title": "Trends in Molecular Medicine",
"key": "2022112911400656000_2022.11.24.517882v1.65",
"volume": "28",
"year": "2022"
},
{
"DOI": "10.1016/j.molmed.2022.07.009",
"article-title": "The spike hypothesis in vaccine-induced adverse effects: questions and answers",
"doi-asserted-by": "crossref",
"first-page": "797",
"journal-title": "Trends in Molecular Medicine",
"key": "2022112911400656000_2022.11.24.517882v1.66",
"volume": "28",
"year": "2022"
},
{
"DOI": "10.3390/s21175857",
"article-title": "Monitoring Serum Spike Protein with Disposable Photonic Biosensors Following SARS-CoV-2 Vaccination",
"doi-asserted-by": "crossref",
"first-page": "5857",
"journal-title": "Sensors",
"key": "2022112911400656000_2022.11.24.517882v1.67",
"volume": "21",
"year": "2021"
},
{
"DOI": "10.1093/cid/ciab465",
"article-title": "Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients",
"doi-asserted-by": "crossref",
"first-page": "715",
"journal-title": "Clin Infect Dis",
"key": "2022112911400656000_2022.11.24.517882v1.68",
"volume": "74",
"year": "2022"
},
{
"DOI": "10.1016/j.cell.2022.01.018",
"article-title": "Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination",
"doi-asserted-by": "crossref",
"first-page": "1025",
"journal-title": "Cell",
"key": "2022112911400656000_2022.11.24.517882v1.69",
"volume": "185",
"year": "2022"
},
{
"DOI": "10.56098/ijvtpr.v2i2.47",
"article-title": "Dark Field Microscopic Analysis on the Blood of 1,006 Symptomatic Persons After Anti-COVID mRNA Injections from Pfizer/BioNTech or Moderna",
"doi-asserted-by": "crossref",
"first-page": "385",
"journal-title": "International Journal of Vaccine Theory, Practice, and Research",
"key": "2022112911400656000_2022.11.24.517882v1.70",
"volume": "2",
"year": "2022"
},
{
"DOI": "10.3390/tropicalmed7080196",
"article-title": "Cardiovascular Manifestation of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents",
"doi-asserted-by": "crossref",
"first-page": "196",
"journal-title": "Tropical Medicine and Infectious Disease",
"key": "2022112911400656000_2022.11.24.517882v1.71",
"volume": "7",
"year": "2022"
},
{
"DOI": "10.1007/BF00316107",
"doi-asserted-by": "publisher",
"key": "2022112911400656000_2022.11.24.517882v1.72"
},
{
"article-title": "Spreading of a new SARS-CoV-2 N501Y spike variant in a new lineage",
"first-page": "1352",
"journal-title": "Clin Microbiol Infect",
"key": "2022112911400656000_2022.11.24.517882v1.73",
"volume": "27",
"year": "2021"
},
{
"DOI": "10.3390/v13112177",
"doi-asserted-by": "publisher",
"key": "2022112911400656000_2022.11.24.517882v1.74"
},
{
"DOI": "10.1093/cid/ciac143",
"article-title": "Omicron Variant Escapes Therapeutic Monoclonal Antibodies (mAbs) Including Recently Released Evusheld®, Contrary to 8 Prior Main Variant of Concern (VOC)",
"doi-asserted-by": "crossref",
"first-page": "e534",
"journal-title": "Clinical Infectious Diseases",
"key": "2022112911400656000_2022.11.24.517882v1.75",
"volume": "75",
"year": "2022"
},
{
"DOI": "10.1038/s41564-020-0770-5",
"article-title": "A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology",
"doi-asserted-by": "crossref",
"first-page": "1403",
"journal-title": "Nature Microbiology",
"key": "2022112911400656000_2022.11.24.517882v1.76",
"volume": "5",
"year": "2020"
},
{
"DOI": "10.1038/s41467-021-22045-y",
"article-title": "A haemagglutination test for rapid detection of antibodies to SARS-CoV-2",
"doi-asserted-by": "crossref",
"first-page": "1951",
"journal-title": "Nat Commun",
"key": "2022112911400656000_2022.11.24.517882v1.77",
"volume": "12",
"year": "2021"
},
{
"DOI": "10.1016/j.jinf.2021.06.001",
"doi-asserted-by": "publisher",
"key": "2022112911400656000_2022.11.24.517882v1.78"
},
{
"DOI": "10.1093/nar/gkh468",
"doi-asserted-by": "publisher",
"key": "2022112911400656000_2022.11.24.517882v1.79"
},
{
"DOI": "10.1002/elps.1150181505",
"doi-asserted-by": "publisher",
"key": "2022112911400656000_2022.11.24.517882v1.80"
}
],
"reference-count": 80,
"references-count": 80,
"relation": {},
"resource": {
"primary": {
"URL": "http://biorxiv.org/lookup/doi/10.1101/2022.11.24.517882"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subtitle": [],
"subtype": "preprint",
"title": "SARS-CoV-2 Spike Protein Induces Hemagglutination: Implications for COVID-19 Morbidities and Therapeutics and for Vaccine Adverse Effects",
"type": "posted-content"
}